Bemiparin as a Prophylaxis After an Unexplained Stillbirth: Open-Label Interventional Prospective Study

Clin Appl Thromb Hemost. 2019 Jan-Dec:25:1076029619896629. doi: 10.1177/1076029619896629.

Abstract

Stillbirth is a devastating event to the parents, relatives, friends, and families. The role of anticoagulants in the prevention of unexplained stillbirths is uncertain. An open-label interventional prospective cohort study was conducted on 144 women with a history of unexplained stillbirths. The intervention group had a high umbilical artery resistance index (RI) and received bemiparin. The nonintervention group had a normal RI and did not receive any intervention. We measured the adjusted odds ratio (OR) and 95% confidence interval (CI) of the main outcome for these variables using logistic regression analysis. Fresh stillbirth and early neonatal death rates were lower (P = .005, OR = 11.949 and 95% CI = 2.099-68.014) and newborn weight was higher (P = .015, OR = 0.048, 95% CI = 0.004-0.549) in the group that received bemiparin. Bemiparin is effective in decreasing the rate of stillbirth in women with a history of previous unexplained stillbirths.

Keywords: Doppler ultrasound; low-molecular-weight heparin; resistant index; stillbirths.

MeSH terms

  • Adult
  • Anticoagulants / pharmacology
  • Anticoagulants / therapeutic use*
  • Cohort Studies
  • Female
  • Heparin, Low-Molecular-Weight / pharmacology
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Pregnancy
  • Prospective Studies
  • Stillbirth*

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • bemiparin